Drug discovery requires two separate steps: checking whether a drug can bind to a harmful molecule or its receptor, and ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." The 2-2-2 method was created by Ian K. Smith, MD, author of The Met Flex Diet: Burn Better Fuel, Burn ...

ETFs offer a convenient way for investors to gain broad, diversified exposure to stocks. It's hard to beat Vanguard's S&P 500 ETF, which has delivered excellent results over time. Vanguard's ...

The Northrop B-2 Spirit is one of the United States Air Force's most well-known and fascinating aircraft. The heavy strategic bomber can fly to and drop ordnance on targets anywhere in the world, and ...

Derek's love of games came at an early age when his parents first brought home the Nintendo Entertainment System. From then on, countless nights were spent hunting ducks, stomping turtles, exploring ...

While we may have gotten away with high-volume, high-intensity training and minimal recovery in our twenties, we lose some of that flexibility as time goes on. Gone are the days when we could down a ...

(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...

-- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the ...